The effects of beta blockers on long-term morbidity and mortality have been established
in patients with chronic heart failure with reduced left ventricular function. Among
various beta blockers, only carvedilol and bisoprolol are approved by Japanese guidelines
for treatment of patients with chronic heart failure. Bisoprolol is highly selectivity
for the beta-1 receptor, while carvedilol is a non-selective beta blocker with simultaneous
alpha receptor antagonist effects. BNP and NT-proBNP are established biomarkers used
in the diagnosis and prognosis of chronic heart failure. Recently, hsTnT, which is
released by injured myocardial tissue, has also been investigated as a marker of heart
failure. Although several reports have compared bisoprolol and carvedilol in patients
with chronic heart failure in Japan as well as in western countries, these reports
did not focus on hsTnT levels. We thus designed the “Bisoprolol Improvement Group
for chronic heart failure treatment study in Dokkyo Medical University” (BRIGHT-D)
to directly compare drug tolerability, heart failure symptoms, biomarkers and cardiac
function between bisoprolol and carvedilol in patients with chronic heart failure
with reduced ejection fraction. As a result, bisoprolol might have some potential
advantage over carvedilol in terms of protection against myocardial injury. In this
session, we would like to present and discuss our data.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of Cardiac FailureAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
